Listed

Fate Therapeutics Inc: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 4, 2022 and accepted by EDGAR at May 4, 2022, 16:16 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-01-01 to 2022-03-31$18.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2022-01-01 to 2022-03-31$72.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-01-01 to 2022-03-31−$74.5mus-gaap:OperatingIncomeLoss
Net income3 months2022-01-01 to 2022-03-31−$65.7mus-gaap:NetIncomeLoss
Operating cash flow3 months2022-01-01 to 2022-03-31−$64.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2022-01-01 to 2022-03-31$10.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-03-31$64.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-03-31$599.1mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$858.4mus-gaap:Assets
Current liabilitiesAt period end2022-03-31$77.9mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2022-03-31$633.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-22-007389. Last ingested by Listed: Nov 14, 2026, 10:50 ET. Listed shows no prices and gives no investment advice.